Evaluating a new PET/CT scan for orbital tumors
Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/ CT in Patients With Orbital Neoplasms and Compared With 18F-FDG PET/ CT
This study is testing a new type of PET/CT scan to see if it does a better job at finding orbital tumors compared to the standard scan for people who might have these tumors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 3 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06791226 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effectiveness of 18F-AlF-FAPI PET/CT in diagnosing primary and metastatic orbital neoplasms compared to the standard 18F-FDG PET/CT. Participants with suspected or newly diagnosed orbital tumors will undergo both imaging techniques to evaluate their diagnostic accuracy. The study will quantify tumor uptake and record the number of metastatic lesions identified by each method, calculating sensitivity, specificity, and accuracy for comparison.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected or newly diagnosed orbital neoplasms who are scheduled for both types of PET/CT scans.
Not a fit: Patients who are pregnant, breastfeeding, or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnostic accuracy for patients with orbital neoplasms, leading to better treatment decisions.
How similar studies have performed: While the use of PET/CT imaging is established, the specific application of 18F-AlF-FAPI in this context is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients with suspected or newly diagnosed orbital neoplasms (supporting evidence may include MRI, CT and pathology report); 2. patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans; 3. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: 1. patients with pregnancy; 2. breastfeeding; 3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Beijing, Beijing Municipality
- Dept. of Nuclear Medicine, Peking University Third Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Hui Li
- Email: huilee1990@163.com
- Phone: 86-010-82264935
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.